Security
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares · ZJYL
ZJYLNASDAQCommon stockCurrentCIK 1837821Updated Oct 3, 2026
ZJYL price & chart
Loading TradingView…
NASDAQ:ZJYL on TradingView ↗In the news
No coverage from other publishers is available.
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 53,368,358Source | 45,800,769Source | 32,903,450Source |
| Property, Plant and Equipment, NetUSD | 7,895,385Source | 1,460,286Source | 1,480,796Source |
| Current assets: | |||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,807,386Source | 5,912,035Source | 3,283,266Source |
| Inventory, NetUSD | 4,923,164Source | 5,173,458Source | 5,053,136Source |
| Assets, CurrentUSD | 44,143,213Source | 42,816,216Source | 31,115,815Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,676,136Source | 2,325,029Source | 892,597Source |
| Operating Lease, Right-of-Use AssetUSD | 85,157Source | 256,117Source | 154,364Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 23,795,891Source | 17,248,309Source | 8,924,345Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 7,827Source | 7,827Source | 7,797Source |
| Additional Paid in CapitalUSD | — | 6,749,144Source | 6,437,179Source |
| Retained Earnings (Accumulated Deficit)USD | 20,940,978Source | 20,021,346Source | 16,927,605Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -923,968Source | -556,209Source | -1,404,366Source |
| Stockholders' Equity Attributable to ParentUSD | 29,638,722Source | 28,815,184Source | 23,979,105Source |
| Additional Paid in Capital, Common StockUSD | 6,749,144Source | — | — |
| Liabilities and EquityUSD | 53,368,358Source | 45,800,769Source | 32,903,450Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 23,795,891Source | 17,152,134Source | 8,924,345Source |
| Operating Lease, Liability, CurrentUSD | 72,645Source | 185,154Source | — |
| Accounts Payable, CurrentUSD | 3,256,624Source | 3,012,334Source | 3,391,079Source |
| Operating Lease, Liability, NoncurrentUSD | — | 96,175Source | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -66,255Source | -262,724Source | — |
| Additional Financial Items | |||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | 3,283,266Source |
| Short-term InvestmentsUSD | 22,168,607Source | 18,621,251Source | 9,768,835Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 1,381,245Source | 3,419,835Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 243,403Source | 237,823Source | 225,902Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | -1,284,554Source | 2,386,501Source | -348,730Source |
| Increase (Decrease) in InventoriesUSD | -168,295Source | -80,315Source | -1,555,441Source |
| Increase (Decrease) in Accounts PayableUSD | 287,035Source | -499,570Source | -646,886Source |
| Deferred Income Tax Expense (Benefit)USD | -22,065Source | 36,329Source | 89,603Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 2,903,584Source | -1,207,305Source | 3,106,403Source |
| Cash flows from investing activities: | |||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 500,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -10,791,736Source | -9,514,007Source | -7,730,248Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,629,800Source | 144,949Source | 113,937Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,353,245Source | 11,654,357Source | 6,910,619Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -674,549Source | 1,206,671Source | 2,136,876Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,461,630Source | 8,136,179Source | 6,929,508Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 411,068Source | 239,369Source | 142,730Source |
| Income Taxes Paid, NetUSD | 564,795Source | 205,373Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -139,642Source | 273,626Source | — |
| Additional Financial Items | |||
| AmortizationUSD | 25,996Source | 17,910Source | 4,951Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | 89,602Source |
| DepreciationUSD | 217,407Source | 219,913Source | 220,951Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 23,071Source | -26,774Source | -50,406Source |
| Gain (Loss) on Sale of InvestmentsUSD | 47,500Source | 45,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -36,694Source | -2,586Source | 6,856Source |
| General and Administrative ExpenseUSD | 2,533,438Source | 3,261,752Source | 1,921,367Source |
| Income Tax Expense (Benefit)USD | 214,572Source | 763,879Source | 343,707Source |
| Investment Income, InterestUSD | 789,070Source | 466,524Source | — |
| Net Income (Loss) Attributable to ParentUSD | 1,191,297Source | 3,675,927Source | 2,878,230Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 189,948Source | -256,092Source | — |
| Nonoperating Income (Expense)USD | 987,635Source | 544,966Source | — |
| Operating ExpensesUSD | 5,436,351Source | 5,864,021Source | 3,917,572Source |
| Operating Lease, ExpenseUSD | 193,379Source | 201,176Source | — |
| Other Operating Income (Expense), NetUSD | — | — | 354,675Source |
| Proceeds from Issuance of Common StockUSD | — | 311,995Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 336,638Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 20,687,274Source | 23,502,010Source | 19,821,457Source |
| Cost of RevenueUSD | 14,444,482Source | 13,892,161Source | — |
| Operating Income (Loss)USD | 608,182Source | 3,638,748Source | 2,867,262Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,595,817Source | 4,183,714Source | 3,221,937Source |
| Income Tax Expense (Benefit)USD | 214,572Source | 763,879Source | 343,707Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 189,948Source | -256,092Source | — |
| Net Income (Loss) Attributable to ParentUSD | 1,191,297Source | 3,675,927Source | 2,878,230Source |
| Earnings Per Share, BasicUSD per share | 0.01Source | 0.02Source | 0.02Source |
| Earnings Per Share, DilutedUSD per share | 0.01Source | 0.02Source | 0.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 156,547,100Source | 156,474,149Source | 145,136,980Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 156,547,100Source | 156,474,149Source | 145,598,860Source |
| Additional Financial Items | |||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 23,071Source | -26,774Source | -50,406Source |
| General and Administrative ExpenseUSD | 2,533,438Source | 3,261,752Source | 1,921,367Source |
| Gross ProfitUSD | 6,044,533Source | 9,502,769Source | 6,784,834Source |
| Interest Income (Expense), NetUSD | — | — | 182,682Source |
| Interest Income, OperatingUSD | 878,652Source | 678,411Source | — |
| Interest Income, OtherUSD | — | — | 117,213Source |
| Investment Income, InterestUSD | 789,070Source | 466,524Source | — |
| Nonoperating Income (Expense)USD | 987,635Source | 544,966Source | — |
| Operating ExpensesUSD | 5,436,351Source | 5,864,021Source | 3,917,572Source |
| Operating Lease, ExpenseUSD | 193,379Source | 201,176Source | — |
| Other Cost of Operating RevenueUSD | — | — | 12,856,556Source |
| Other IncomeUSD | — | — | 222,399Source |
| Other Operating Income (Expense), NetUSD | — | — | 354,675Source |
| Research and Development ExpenseUSD | 1,557,703Source | 1,497,325Source | 1,542,894Source |
| Revenue Not from Contract with Customer, OtherUSD | — | — | 1,022,358Source |
| Selling ExpenseUSD | 1,345,210Source | 1,104,944Source | 453,311Source |
Filing attachments
jinex99-1.htm · SCHEDULE 13G · 2026-08-18
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13G-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A ordinary shares, par value of US$0.001 per share, of JIN MEDICAL INTERNATIONAL LTD., a Cayman Island…
Read attachment ↗